Evidence map›Paper›PMID 40221437›Full record

ArticleNature communications2025

Mutant CEBPA promotes tolerance to inflammatory stress through deficient AP-1 activation.

Maria Cadefau-Fabregat, Gerard Martínez-Cebrián, Lucía Lorenzi, Felix D Weiss, Anne-Katrine Frank, José Manuel Castelló-García, Eric Julià-Vilella, Andrés Gámez-García, Laura Yera, Carini Picardi Morais de Castro and 6 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Maria Cadefau-FabregatJosep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.ORCID http://orcid.org/0000-0001-5915-3202
Gerard Martínez-Cebrián *Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
Lucía Lorenzi *Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.ORCID http://orcid.org/0000-0003-3834-2658
Felix D WeissInstitute of Innate Immunity, Department for Systems Immunology and Proteomics, Medical Faculty, University Hospital Bonn, University of Bonn, 53127, Bonn, Germany.ORCID http://orcid.org/0000-0003-0228-5081
Anne-Katrine FrankThe Finsen Laboratory, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
José Manuel Castelló-GarcíaChromatin Biology Laboratory, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
Eric Julià-VilellaJosep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
Andrés Gámez-GarcíaChromatin Biology Laboratory, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.ORCID http://orcid.org/0000-0003-4927-3678
Laura YeraJosep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
Carini Picardi Morais de CastroJosep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
Yi-Fang WangMRC London Institute of Medical Sciences, Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, Du Cane Road, London, W12 0NN, UK.
Felix MeissnerInstitute of Innate Immunity, Department for Systems Immunology and Proteomics, Medical Faculty, University Hospital Bonn, University of Bonn, 53127, Bonn, Germany.ORCID http://orcid.org/0000-0003-1000-7989
Alejandro VaqueroChromatin Biology Laboratory, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.ORCID http://orcid.org/0000-0002-8735-4156
Matthias MerkenschlagerMRC London Institute of Medical Sciences, Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, Du Cane Road, London, W12 0NN, UK.ORCID http://orcid.org/0000-0003-2889-3288
Bo T PorseThe Finsen Laboratory, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-6043-0844
Sergi CuarteroJosep Carreras Leukaemia Research Institute (IJC), Badalona, Spain. scuartero@carrerasresearch.org.ORCID http://orcid.org/0000-0002-9338-583X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The CEBPA transcription factor is frequently mutated in acute myeloid leukemia (AML). Mutations in the CEBPA gene, which are typically biallelic, result in the production of a shorter isoform known as p30. Both the canonical 42-kDa isoform (p42) and the AML-associated p30 isoform bind chromatin and activate transcription, but the specific transcriptional programs controlled by each protein and how they are linked to a selective advantage in AML is not well understood. Here, we show that cells expressing the AML-associated p30 have reduced baseline inflammatory gene expression and display altered dynamics of transcriptional induction in response to LPS, consequently impacting cytokine secretion. This confers p30-expressing cells an increased resistance to the adverse effects of prolonged exposure to inflammatory signals. Mechanistically, we show that these differences primarily arise from the differential regulation of AP-1 family proteins. In addition, we find that the impaired function of the AP-1 member ATF4 in p30-expressing cells alters their response to ER stress. Collectively, these findings uncover a link between mutant CEBPA, inflammation and the stress response, potentially revealing a vulnerability in AML.

Indexed as

CCAAT-Enhancer-Binding ProteinsInflammationLeukemia, Myeloid, AcuteTranscription Factor AP-1Activating Transcription Factor 4AnimalsCell Line, TumorEndoplasmic Reticulum StressHumansLipopolysaccharidesMiceMutationProtein IsoformsActivating Transcription Factor 4ATF4 protein, humanCCAAT-Enhancer-Binding ProteinsCEBPA protein, humanLipopolysaccharidesProtein IsoformsTranscription Factor AP-1

Identifiers

PMID40221437
PMCPMC11993602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.